Further Information
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial, 70 kDa mitochondrial autoantigen of primary biliary cirrhosis, PBC, Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex, M2 antigen complex 70 kDa subunit, Pyruvate dehydrogenase complex component E2, PDC-E2, PDCE2, DLAT, DLTA
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:10~50
For FACS starting dilution is: 1:10~50
DLAT encodes component E2 of the multi-enzyme pyruvate dehydrogenase complex (PDC). PDC resides in the inner mitochondrial membrane and catalyzes the conversion of pyruvate to acetyl coenzyme A. The protein product of this gene, dihydrolipoamide acetyltransferase, accepts acetyl groups formed by the oxidative decarboxylation of pyruvate and transfers them to coenzyme A. Dihydrolipoamide acetyltransferase is the antigen for antimitochondrial antibodies. These autoantibodies are present in nearly 95% of patients with the autoimmune liver disease primary biliary cirrhosis (PBC). In PBC, activated T lymphocytes attack and destroy epithelial cells in the bile duct where this protein is abnormally distributed and overexpressed. PBC enventually leads to cirrhosis and liver failure.
- Trynka, G., et al. Gut 58(8):1078-1083(2009)
- Lleo, A., et al. Hepatology 49(3):871-879(2009)
- Korotchkina, L.G., et al. FEBS Lett. 582(3):468-472(2008)
Supplied in PBS with 0.09% (W/V) sodium azide.
batch dependent
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
This DLAT antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 579-607 amino acids from the C-terminal region of human DLAT.
1737
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial
DLAT
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
69 kDa
P10515
215274207
This antibody is purified through a protein A column, followed by peptide affinity purification.
Cancer,Obesity,Signal Transduction
P10515
Optimal dilutions for each application to be determined by the researcher.